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Abstract
Objective: To demonstrate that hypolipidemia is a typical feature of the mouse model of amyotrophic lateral sclerosis (ALS)
and to assess the association between hypolipidemia and disease stage, dietary intake, and sex.
Methods: We compared daily dietary intake, body weight, and serumlipid and glucose levels in ALS mice and wild-type
controls at different stages of the disease.
Findings: Total cholesterol low-density lipoprotein (LDL) and LDL/high-density lipoprotein (HDL) ratio were significantly
lower in ALS mice compared with controls. Subgroup analysis revealed that the incidence of hypolipidemia was significantly
greater in male, but not female, ALS mice compared with control mice and that hypolipidemia was present at the
presymptomatic stage of the disease. This hypolipidemia can be found without a decrease in the serum levels of other
energy sources, such as glucose, in the presymptomatic stage.
Conclusions: Hypolipidemia is present at the presymptomatic stage of the ALS mouse model in the absence of
malnutrition, significant neuromuscular degeneration or regeneration, and respiratory difficulty. Our findings suggest that
hypolipidemia might be associated with the pathomechanism of ALS and/or lipid-specific metabolism rather than simply an
epiphenomenon of neuromuscular degeneration or energy imbalance.
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Introduction
Amyotrophic lateral sclerosis (ALS) is an adult-onset progressive
neurodegenerative disease that affects the motor neurons of the
cerebral cortex, brainstem, and spinal cord and typically causes
death within 5 years from onset [1,2]. It has long been recognized
as a disease of the motor neurons; however, increasing evidence
suggests the involvement of extra-motor neurons [3,4] and
extraneuronal tissue in the pathogenesis of ALS [1,5]. Recent
studies have detected abnormal lipid metabolism in ALS and
investigated its cause [6–8], its role in the disease progression
[9,10], and its association with other systemic factors [10].
Despite the finding of abnormal lipid metabolism in ALS,
conflicting results have been reported for basal serum lipid levels
[8,9,10], the cause of dyslipidemia [7,10], and the relationship
between serum lipid levels and respiratory function and/or disease
progression [10]. Moreover, it is unclear whether the dyslipidemia
is the result of a specific need for lipids or a non-specific need for
energy, and the role of serum lipid in ALS is further confused
because several studies do not distinguish between these
hypotheses [8,11,12].
We hypothesized that hypolipidemia in ALS is related to the
pathogenesis of the disease and not secondary to peripheral
neuromuscular system or respiratory function. Furthermore, we
hypothesized that the hypolipidemia is independent of the
depletion of other energy sources such as glucose.
Methods
ALS mice
B6SJL-Tg(SOD1-G93A)1Gur/J mice with a high copy number
of transgenic human mutant superoxide dismutase 1s (SOD1s),
which contained a glycine 93 (Gly93) to alanine (Ala) substitution
(Strain No. 002726), were obtained from the Jackson Laboratory
(Bar Harbor, ME, USA) [13]. The mice were housed under a 12-h
light/dark cycle and bred as per the supplier’s protocol [14]. The
presence of the human G93A transgene was confirmed with
polymerase chain reaction (PCR) assays using DNA extracted
from the tail tissue. In this strain, the first ALS symptoms and end-
stage symptoms appear at approximately 77 days and 136 days of
age, respectively [15,16]; thus, we divided 30 transgenic mice (15
male) into three equal-sized age groups: 60 (presymptomatic), 90
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(early symptomatic), and 120 days (late symptomatic). They were
fed a chow diet (LAB rodent CHOW; 38057; Cargill Agri Purina,
Inc, Korea) Thirty age- and sex-matched wild-type mice served as
controls. The mice in each age group were fasted for 6 h [17] and
euthanized using deep inhalation of isoflurane, and then blood was
collected via cardiac puncture. The blood was centrifuged and the
serum was preserved in a deep freezer. Serum cholesterol (Catalog
NO: HC0721/0722), low-density lipoprotein (LDL, HC2210),
high-density lipoprotein (HDL, HC2110), and triglycerides (TG,
HC0821/0822), were quantified using enzymatic assays (HBI Co.,
Anyang, Korea). Protein (HC1421) and glucose (HC0621/0622)
levels were quantified using the Biuret assay and Trinder glucose
activity test, respectively. The daily dietary intake of each mouse
was measured for 5 consecutive days before the mouse was
euthanized, and body weight was measured at 1 and 5 days before
the mice were euthanized.
The animal study procedures were approved by the Institutional
Animal Care and Use Committee (IACUC) of Hanyang
University. (Permit number: 09-032).
Statistical analyses
We compared the mean serum levels of cholesterol, TG, LDL,
HDL, and glucose in the ALS and control mice using the Mann–
Whitney U-test. Statistical analyses were performed using the
Statistical Package for Social Sciences (SPSS) version 17.0, and
p,0.05 was considered to be statistically significant. Results are
expressed as mean 6 standard deviation, throughout the text.
Results
Hypolipidemia in the ALS mice of all age and age-sex
matched controls. (Figure 1, left panel)
A comparison of the all pre-symptomatic, early symptomatic,
and late symptomatic ALS mice (n = 30) and control mice (n = 30)
showed that the ALS mice had significantly lower serum
cholesterol (83.45 mg/dL612.83 vs. 94.29619.75 mg/dL, re-
spectively; p=0.011), LDL (13.57 mg/dL63.13 vs. 17.906
7.23 mg/dL, p=0.003), and LDL/HDL ratio (0.2260.05 vs.
0.2660.08, p=0.010) than did the control mice (Figure. 1, left
panel). Dietary intake did not differ between the ALS mice and
controls (3.7960.51 g/day vs. 3.9360.62 g/day, p = 0.543),
suggesting that the hypolipidemia was not the result of dysphagia
or poor dietary intake (Figure. 1,A–C,E, left panel).
Hypolipidemia in the pre-symptomatic ALS mice and
age-sex matched controls. (Figure 1, right panel)
The analysis of serum levels of lipid, glucose, dietary intake and
body weight were also performed according the different disease
stage in ALS mice and controls. (Figure 1, right panel) In the
presymptomatic stage (60 days after birth; n= 10), the serum LDL
level was significantly lower in the ALS mice than in the age- and
sex-matched controls (14.5064.45 mg/dL vs. 21.6869.45 mg/
dL, respectively; p=0.043). Furthermore, the serum cholesterol
and the LDL/HDL ratio were lower in the presymptomatic group
than in the controls; however, the values did not reach statistical
significance. Dietary intake in the presymptomatic ALS group did
not differ from that of the age- and sex-matched controls.
(3.9060.30 g/day vs. 3.8663.86 g/day, p = 0.342)
Hypolipidemia and non-specific energy demands
We found no significant difference in serum glucose levels
between the ALS mice of all age (n = 30) and control groups
(252.096109.70 mg/dL vs. 263.83674.50 mg/dL, p= ns), sug-
gesting that the hypolipidemia was not attributable to non-specific
energy demands. (Figure 1D, left panel) The ALS mice were
hypoglycemic, compared with the controls, only in the late
symptomatic stage, (153.00672.34 mg/dL vs. 250.50685.66 mg/
dL, p=0.015) when they may have experienced excessive
metabolic demands for muscle degeneration/regeneration and
respiratory compensation. [10,18], (Figure. 1D, right panel).
Hypolipidemia and sex
Basal serum cholesterol (92.0069.55 mg/dL vs 108.606
13.24 mg/dL, p=0.0 1) and LDL (15.0862.98 mg/dL vs.
21.6367.94 mg/dL, p=0.012) were significantly lower in all
(including pre-symptomatic, early symptomatic, and late symp-
tomatic) male ALS mice (n = 15) compared with the sex-matched
controls. (figure 2; right panel), but not in female ALS mice.
(figure 2; left panel) Hypolipidemia in the male ALS mice
developed in the absence of significant hypoglycemia (Figure. 2C,
right panel).
The comparison of presymptomatic male mice (age 60 days,
n=5) and their age- and sex-matched controls (Figure 3) showed
that the ALS mice had significantly lower serum cholesterol
(97.8066.91 mg/dL vs. 113.8065.54 mg/dL, p=0.008) and
LDL (16.4463.93 mg/dL vs. 2867.93 mg/dL, p=0.016). Though
presymptomatic female mice group (Figure 3, left panel) and early
and late symptomatic mice groups of both sexes (data not shown)
showed a tendency toward lower serum cholesterol and LDL
statistical significance was not reached.
Discussion
In the present study, we observed that (1) hypolipidemia
occurred in ALS mice; (2) the hypolipidemia was not associated
with a decrease in the level of serum glucose, another important
source of energy; (3) significant hypolipidemia was observed in
male, but not female mice; and (4) hypolipidemia was present at
the presymptomatic stage of ALS, particularly in males, when no
significant neuromuscular degeneration or respiratory insufficien-
cy was present.
Our findings are consistent with (1) studies that have reported
an increase in lipid clearance [7], suggesting that a high-fat diet
might be beneficial [8], (2) reports of high metabolic demands in
the early disease stage [6,18,19], suggesting that interference with
lipid metabolism can cause ALS-like symptoms [20], and (3)
reports of a sex effect in the progression [21] or onset of symptoms
[20] in ALS mice. However, our findings are not consistent with
those of two recent retrospective studies: Dupuis et al. [9] observed
hyperlipidemia in patients with ALS, and Chio` et al. [10]
suggested that hypolipidemia in patients with ALS was associated
with respiratory insufficiency. The inconsistency between our
findings and these reports may merely reflect a difference between
the SOD1 mutant ALS mice model and patients with ALS; [22]
however, other factors may account for these discrepancies. First,
the dietary intake of patients with ALS may be affected by several
factors including dysphagia, severe cognitive dysfunction (e.g.,
frontotemporal lobar dementia), depressive mood, and the
presence of a percutaneous endoscopic gastrostomy (PEG) or a
Levin tube for feeding which variables were not controlled for
analysis in previous study on patients with ALS [9]. Second,
hypermetabolism, which can affect serum lipid levels, has been
reported to be more severe in male than in female patients [6];
thus, studies of serum metabolites such as lipid and glucose should
be analyzed according to sex. However, Dupuis et al. [9] and Chio`
et al. [10] did not assess sex differences in lipid and glucose levels.
Finally, fasting time has a significant influence on basal serum lipid
Hypolipidemia in ALS Mice
PLoS ONE | www.plosone.org 2 March 2011 | Volume 6 | Issue 3 | e17985
levels, and the presence or absence of fasting can affect the relative
level of serum lipid in patients with ALS compared with control
patients [8]. Dupuis et al. did not clearly describe the patient
fasting time.
The results of our study indicate that hypolipidemia in ALS
mice is not associated with decreased food intake, malnutrition,
demand for non-specific energy generation [11], degeneration or
regeneration of muscle [8], or respiratory insufficiency [10] for the
following reasons: hypolipidemia was observed in ALS mice that
had normal food intake; the basal serum glucose level, an
important energy source that may be affected by the nutritional
intake, did not differ between ALS and control mice despite the
presence of hypolipidemia in the ALS mice; and hypolipidemia
was observed at the presymptomatic stage, particularly in male
mice (Figure 1B and 3), when neither significant motor weakness
nor muscle degeneration was present [15].
The serum glucose levels in the ALS mice were not significantly
different from those of the controls until the late symptomatic stage
Figure 1. Basal serum levels of cholesterol (A), low-density lipoprotein (B), LDL/HDL ratio (C), glucose (D), and mean daily dietary
intake (E), and average weight (F). The left panels show the combined value for ALS mice of all age (Tg, n = 30) and the control mice (Wt). The
right panels show the values for the ALS mice and controls in each age group. (n = 10, for each group) Values in the boxes and whisker plots are
median values and interquatile ranges respectively. LDL: low-density lipoprotein, HDL: high-density lipoprotein. * p,0.05.
doi:10.1371/journal.pone.0017985.g001
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(Figure. 1D, right panel). At this stage, the decrease in serum
glucose may have been the result of an increased need for
regeneration of the neuromuscular system or a high demand to
compensate for respiratory muscle weakness. However, this
finding does not alter our conclusion because the ALS mice were
euglycemic as well as hypolipidemic at the presymptomatic stage.
In the present study, the male, but not the female, ALS mice
showed statistically significant hypolipidemia compared with the
age-and sex-matched controls (Figure 2). The reasons for this sex
difference are not clear and may reflect lack of statistical power as
numbers in each group (n= 5) were small. However, previous
studies have shown that knockout of the liver X receptor b (LXRb)
gene, which is associated with cholesterol metabolism in the
central nervous system (CNS), produced ALS symptoms and
resulted in motor neuron degeneration in male, but not female,
mice [21]. Furthermore, hypermetabolism has been reported to be
Figure 2. Basal serum levels of cholesterol (A), low-density lipoprotein (B), and glucose (C) according to sex in ALS mice of all age
(Tg) groups (n=15, for each group) and age- and sex-matched controls (Wt). The basal serum cholesterol and low-density lipoprotein were
significantly lower in male ALS mice compared with control mice. Values in the boxes and whisker plots are median values and interquatile ranges
respectively. LDL: low-density lipoprotein, HDL: high-density lipoprotein. * p,0.05.
doi:10.1371/journal.pone.0017985.g002
Figure 3. The basal serum levels of cholesterol (A) and low-density lipoprotein (B) in female (left panel) and male (right panel) pre-
symptomatic ALS (Tg, aged 60 days) and control (Wt) mice. (n = 5, for each group) The basal serum cholesterol and low-density lipoprotein
levels were significantly lower in male (right panel), but not in female ALS mice (left ) compared with control mice. Values in the boxes and whisker
plots are median values and interquatile ranges respectively. LDL: low-density lipoprotein. * p,0.05.
doi:10.1371/journal.pone.0017985.g003
Hypolipidemia in ALS Mice
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more severe in male, compared with female, patients with ALS
[18], and estrogen has been shown to delay the disease progression
in ALS mice [20]. These findings indicate possible differences in
metabolism between men and women with ALS.
The factors underlying the increased demand for lipids and/or
hypolipidemia in ALS are not known. Previous studies have
suggested that the skeletal muscle activity is the cause of
hypermetabolism in ALS; however, that hypothesis was based
on results showing an increase in glucose uptake rather than lipid
levels [8]. A lipid-specific metabolic abnormality in ALS is
suggested by our results, together with studies showing that a
high-fat diet may alter the CNS pathology (i.e., death of motor
neurons) [8] and that inactivation of the LXRb gene, which
participates in cholesterol transport from glial cells to neurons in
the CNS, caused motor neuron degeneration in mice [21], as well
as by evidence that the CNS, as well as the skeletal muscles, may
contribute to the high lipid demand which might be associated
with ALS pathogenesis [7].
Our study has several limitations. First, the number of mice in
the study was small; thus, although the ALS mice in the
presymptomatic group showed a tendency toward lower serum
cholesterol and LDL/HDL ratio, statistical significance was not
reached. Second, we demonstrated that ALS mice are hypolipid-
emic, but could not identify the underlying mechanism. Last, our
data might have been more valuablehad we been able to take
sequential serum samples from the same mice as the disease
progress. However, because the volume of serum in ALS mice
were too small (especially in 60 days after birth), we could only get
a large enough volume of serum taken at three different specific
time points, by cardiac puncture after general anesthesia, which
inevitably led to the sacrifice of mice due to circulatory collapse.
Nevertheless, our study confirmed the finding that ALS is
associated hypolipidemia prior to the onset of symptoms and a
decrease in respiratory function [8,10] and showed a sex difference
in the metabolic abnormalities of ALS mice. Furthermore, our
findings suggest a lipid-specific metabolic deterioration in ALS
because hypolipidemia is observed in the absence of hypoglyce-
mia, particularly at the presymptomatic stage. Together these
findings suggest that hypolipidemia in ALS is not an epiphenom-
enon of neuromuscular degeneration, respiratory difficulty, or
energy imbalance, but might be associated with the disease
pathomechanism and/or lipid-specific metabolism. Further studies
are required to determine the cause, roles, and sex differences
associated with the high lipid demand in ALS.
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